Dr Roger Aston was the CEO of Mayne Pharma, which at the time was valued at more than AUD1bn in 2012.
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals.
Roger is currently he CEO and Chairman of PharmAust, which is listed on the ASX under ticker PAA.
PAA is a clinical-stage company developing targeted cancer therapeutics to address both human and animal healthcare. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, which is a highly successful contract medicinal chemistry company that generates significant annual revenues.
Copyright © Track Record